Prosecution Insights
Last updated: October 26, 2026

Andrew Peter Restaino, USPTO Patent Examiner

Listed by the USPTO as RESTAINO, ANDREW PETER

Tech Center 3700 • Art Units: 3771 3796

This examiner grants 72% of resolved cases

Analysis

RESTAINO, ANDREW PETER is assigned to tech center 3700 and art unit 3771. The profile includes 286 resolved cases, a 72.4% allowance rate, and a median of 1032 days to allowance. The interview lift is 39.2%, showing a substantial positive association between interviews and allowance outcomes compared with the profile’s overall result.

The listed companies are Edwards Lifesciences Corporation, Boston Scientific Corporation, and Microvention Inc. The listed firms are SEAGER, TUFTE & WICKHEM, LLP, HARNESS DICKEY (DETROIT), and Shih IP Law Group, PLLC. Counsel may therefore prioritize focused examiner interviews alongside carefully developed written responses. The median pendency indicates that this approach should be integrated into a longer prosecution plan rather than treated as a quick path to disposition.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

72.4%
Allow Rate
+2.4% vs TC avg
347
Total Applications
+39.2%
Interview Lift
1032
Avg Prosecution Days
Based on 286 resolved cases, 2023–2026

Rejection Statute Breakdown

0.9%
§101 Eligibility
25.2%
§102 Novelty
44.5%
§103 Obviousness
25.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18654479 System For Effecting And Controlling Oscillatory Pressure Within Balloon Catheters For Fatigue Fracture Of Calculi Final Rejection The Regents of The University of Michigan
18596039 Technique For Determining A Patient-Specific Marker Arrangement For A Tracker Of A Surgical Tracking System Non-Final OA Stryker European Operations Limited
18931673 ELECTRICALLY ENHANCED RETRIEVAL OF MATERIAL FROM VESSEL LUMENS Non-Final OA Covidien LP
18987281 GAP SEALING SYSTEM AND KIT Final Rejection BOSTON SCIENTIFIC SCIMED, INC.
18930183 DELIVERY DEVICE FOR OCCLUSIVE IMPLANTS Final Rejection Boston Scientific Scimed, Inc.
19192595 GAP COVERING EXPANDABLE IMPLANT FOR PREVENTING BLOOD LEAKAGE BETWEEN THERAPEUTIC DEVICE AND TISSUE AND ASSOCIATED DEVICES, SYSTEMS, AND METHODS Non-Final OA KONINKLIJKE PHILIPS N.V.
18940504 PERICARDICAL TRANSECTION DEVICES AND METHOD Final Rejection EDWARDS LIFESCIENCES CORPORATION
18097365 EXPANDABLE INTRODUCER FOR DILATING THE DISTAL TIP OF AN INTRODUCER SHEATH Final Rejection Edwards Lifesciences Corporation
17812669 SYSTEMS AND METHODS FOR FLUID CONTROL Final Rejection Edwards Lifesciences Corporation
18507310 Proximal Element Actuator Fixation And Release Mechanisms Non-Final OA Evalve, Inc.
19071519 MEDICAL DEVICE Non-Final OA OLYMPUS MEDICAL SYSTEMS CORP.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Andrew Peter Restaino's allowance rate?

72.4% of resolved applications examined by Andrew Peter Restaino were allowed (286 resolved cases), compared with 65.9% across Art Unit 3771 over the last five years.

Does an interview help with examiner Andrew Peter Restaino?

This examiner's interview lift is +39.2 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Andrew Peter Restaino take to allow a patent?

Applications allowed by Andrew Peter Restaino took 1,032 days on average from filing to allowance.

Which art unit does examiner Andrew Peter Restaino work in?

Andrew Peter Restaino examines applications in Art Unit 3771 in Tech Center 3700 (Medical Devices & Mechanical Engineering).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month